Form 4: Verastem Director Receives Stock Grant

Verastem, Inc. reports that Director Eric K. Rowinsky was granted 36,000 Restricted Stock Units (RSUs) on May 21, 2026.

Summary

• Eric K. Rowinsky, a Director at Verastem, Inc., was granted 36,000 Restricted Stock Units (RSUs) on May 21, 2026.
• These RSUs are part of the Issuer's Amended and Restated 2021 Equity Incentive Plan.
• Each RSU represents the right to receive one share of Common Stock.
• The RSUs will vest in twelve installments, with the first eleven vesting monthly from June 2026 to April 2027, and the final installment vesting on the earlier of the day before the 2027 Annual Meeting of Stockholders or May 31, 2027.
• Vesting is contingent upon continued service as a director on each vesting date.
• Following this grant, Rowinsky beneficially owns 52,666 shares of Common Stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, reflecting standard compensation practices for directors and a commitment to long-term alignment.

Positives

• Director Eric K. Rowinsky received a significant grant of 36,000 RSUs, indicating continued investment in leadership and alignment with shareholder interests.
• The grant is structured with a vesting schedule, encouraging long-term commitment from the director.
• The total beneficial ownership of Rowinsky increases to 52,666 shares, demonstrating a substantial stake in the company.

Risks

• Vesting of RSUs is contingent on continued service as a director, meaning any departure before vesting dates could result in forfeiture of unvested units.
• The value of the RSUs is tied to the future performance of Verastem, Inc.'s common stock, which is subject to market volatility.

Future Outlook

The vesting schedule for the RSUs extends through May 2027, indicating a forward-looking commitment from the director to remain with the company through that period.

Industry Context

StockSavvy.ai notes that grants of Restricted Stock Units (RSUs) to directors are a common practice in the biotechnology and pharmaceutical sectors, aligning executive and director compensation with long-term company performance and shareholder value.

Stakeholder Impact

• Shareholders: The grant aligns director incentives with shareholder interests through equity ownership and a vesting schedule tied to continued service.
• Employees: This filing does not directly impact employees but reflects the company's compensation structure for its board.
• Management: Reinforces the company's commitment to retaining key leadership through equity incentives.

Next Steps

• Continued service by Eric K. Rowinsky as a director to meet vesting conditions.
• Vesting of RSUs according to the specified schedule.

Key Dates

Keywords

Verastem, VSTM, Form 4, SEC Filing, Stock Grant, RSU, Director Compensation, Equity Incentive Plan, Beneficial Ownership